News

NICE fears drug appraisals will suffer after appeal

02-May-08

Drug appraisals could take longer, claims NICE after the Court of Appeal ruled that it must make the way it calculates cost-effectiveness more open.

Yesterday, Eisai, manufacturers of the Alzheimer's drug donepezil (Aricept), won its argument to be given an executable version of the economical model used by NICE when it decided the drug should not be given to patients with mild Alzheimer's disease.

NICE chief executive Andrew Dillon said: ‘The ruling will increase the complexity of our drug appraisals in some cases and they may take longer as a result. 

‘In the meantime, and in accordance with the judges' ruling, we will provide Eisai with an executable version of the economical model used in our appraisal, so that it can comment on it,' he added.

‘We will then take those comments into account.' 

Although a ‘read-only'version of NICE's economic model is available, the Court of Appeal ruled that an ‘executable' version including additional functions and calculations was made available to Eisai.

NICE said the economical model is put together differently for each technology appraisal. The ruling applies to this individual case and may not be borne out in other appeals. 

The Association of the British Pharmaceutical Industry (ABPI) welcomed the Court of Appeal ruling.

‘This judgement provides further momentum behind the drive to make NICE processes more transparent,' said ABPI director general Dr Richard Barker.

rachel.liddle@haymarket.com

Do you think NICE needs to be more transparent? Comment below and tell us what you think.

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Registrar

Assessment guide is useful for all

Mock scenarios and helpful exercises make this book more than an exam guide, says Dr Lizzie Croton. Read more

Women's health - Terminate pregnancies

Requests for pregnancy termination should be handled with sensitivity, writes Dr Mona Kular. Read more

Clinical skills assessment

In the first of a regular look at the nMRCGP, Dr Daryl Goodwin explains how to pass the CSA. Read more

Show all articles

 

Latest Clinical Articles

Sjogren's syndrome

Contributed by Dr Jeffery Lee, consultant rheumatologist, Barnet Hospital, Hertfordshire. Read more

Chronic kidney disease

Section 1: Epidemiology and classification  Chronic kidney disease (CKD) encompasses abnor... Read more

Acute kidney injury

Contributed by Dr Stephan Brincat, specialist registrar, and Dr Rachel Hilton, consultant nephrologi... Read more

Show all clinical articles

MIMS Product News

New drug - Eucreas

Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequate... Read more

New drug - Galvus

Novartis has launched a new oral hypoglycaemic for the treatment type II diabetes. Read more

Coversyl formulation change

Coversyl and Coversyl Plus have been discontinued and replaced by Coversyl Arginine and Coversyl Arg... Read more

Jobs

 

Job of the Week